

Massimo Andreoni

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3930625/publications.pdf>

Version: 2024-02-01

199
papers

4,361
citations

117453

34
h-index

161609

54
g-index

204
all docs

204
docs citations

204
times ranked

5842
citing authors

#	ARTICLE	IF	CITATIONS
1	Low Vitamin D Status at Admission as a Risk Factor for Poor Survival in Hospitalized Patients With COVID-19: An Italian Retrospective Study. <i>Journal of the American College of Nutrition</i> , 2022, 41, 250-265.	1.1	41
2	Milestones to reach Hepatitis C Virus (HCV) elimination in Italy: From free-of-charge screening to regional roadmaps for an HCV-free nation. <i>Digestive and Liver Disease</i> , 2022, 54, 237-242.	0.4	20
3	Droplet digital PCR assay as an innovative and promising highly sensitive assay to unveil residual and cryptic HBV replication in peripheral compartment. <i>Methods</i> , 2022, 201, 74-81.	1.9	8
4	Optimizing diagnostic algorithms to advance Hepatitis C elimination in Italy: A cost effectiveness evaluation. <i>Liver International</i> , 2022, 42, 26-37.	1.9	8
5	Parietal intrahemispheric source connectivity of resting-state electroencephalographic alpha rhythms is abnormal in Na ⁺ ve HIV patients. <i>Brain Research Bulletin</i> , 2022, 181, 129-143.	1.4	1
6	In Patients with Severe COVID-19, the Profound Decrease in the Peripheral Blood T-Cell Subsets Is Correlated with an Increase of QuantiFERON-TB Gold Plus Indeterminate Rates and Reflecting a Reduced Interferon-Gamma Production. <i>Life</i> , 2022, 12, 244.	1.1	6
7	Highly Sensitive HBsAg, Anti-HBc and Anti HBsAg Titres in Early Diagnosis of HBV Reactivation in Anti-HBc-Positive Onco-Haematological Patients. <i>Biomedicines</i> , 2022, 10, 443.	1.4	4
8	Antimicrobial resistance in the times of COVID-19 in a roman teaching hospital. <i>International Journal of Transgender Health</i> , 2022, 15, 452-457.	1.1	1
9	Depressive and anxiety symptoms in patients with SARS-CoV2 infection. <i>Journal of Affective Disorders</i> , 2021, 278, 339-340.	2.0	11
10	Thymosin Alpha 1 Mitigates Cytokine Storm in Blood Cells From Coronavirus Disease 2019 Patients. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofaa588.	0.4	27
11	Rapid COVID-19 Screening Based on Self-Reported Symptoms: Psychometric Assessment and Validation of the EPICOV19 Short Diagnostic Scale. <i>Journal of Medical Internet Research</i> , 2021, 23, e23897.	2.1	31
12	Estimated prevalence of undiagnosed HCV infected individuals in Italy: A mathematical model by route of transmission and fibrosis progression. <i>Epidemics</i> , 2021, 34, 100442.	1.5	30
13	Addressing HCV Elimination Barriers in Italy: Healthcare Resource Utilization and Cost Impact Using 8-Weeks™ Glecaprevir/Pibrentasvir Therapy. <i>Infectious Diseases and Therapy</i> , 2021, 10, 763-774.	1.8	5
14	The role of dalbavancin for Gram positive infections in the COVID-19 era: state of the art and future perspectives. <i>Expert Review of Anti-Infective Therapy</i> , 2021, 19, 1125-1134.	2.0	11
15	Therapeutic strategies for severe COVID-19: a position paper from the Italian Society of Infectious and Tropical Diseases (SIMIT). <i>Clinical Microbiology and Infection</i> , 2021, 27, 389-395.	2.8	37
16	Evidence of the pathogenic HERV-W envelope expression in T lymphocytes in association with the respiratory outcome of COVID-19 patients. <i>EBioMedicine</i> , 2021, 66, 103341.	2.7	57
17	Baseline T-lymphocyte subset absolute counts can predict both outcome and severity in SARS-CoV-2 infected patients: a single center study. <i>Scientific Reports</i> , 2021, 11, 12762.	1.6	29
18	Real-World Use of Dalbavancin in the Era of Empowerment of Outpatient Antimicrobial Treatment: A Careful Appraisal Beyond Approved Indications Focusing on Unmet Clinical Needs. <i>Drug Design, Development and Therapy</i> , 2021, Volume 15, 3349-3378.	2.0	34

#	ARTICLE	IF	CITATIONS
19	Chems4EU: chemsex use and its impacts across four European countries in HIV-positive men who have sex with men attending HIV services. <i>HIV Medicine</i> , 2021, 22, 944-957.	1.0	27
20	Recommendations of the Italian society for infectious and tropical diseases (SIMIT) for adult vaccinations. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 4265-4282.	1.4	6
21	Genotypic HIV-1 tropism determination might help to identify people with exhausted treatment options and advanced disease. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 3272-3279.	1.3	0
22	Evaluation of S-RBD and high specificity ACE-2-binding antibodies on SARS-CoV-2 patients after six months from infection. <i>International Immunopharmacology</i> , 2021, 99, 108013.	1.7	7
23	Cost-effectiveness analysis of Vaborem in Carbapenem-resistant Enterobacterales (CRE) -Klebsiella pneumoniae infections in Italy. <i>Health Economics Review</i> , 2021, 11, 42.	0.8	3
24	Ceftazidime/Avibactam-Resistant Klebsiella pneumoniae subsp. pneumoniae Isolates in a Tertiary Italian Hospital: Identification of a New Mutation of the Carbapenemase Type 3 (KPC-3) Gene Conferring Ceftazidime/Avibactam Resistance. <i>Microorganisms</i> , 2021, 9, 2356.	1.6	9
25	High CD169 Monocyte/Lymphocyte Ratio Reflects Immunophenotype Disruption and Oxygen Need in COVID-19 Patients. <i>Pathogens</i> , 2021, 10, 1639.	1.2	7
26	Expression profiles of the SARS-CoV-2 host invasion genes in nasopharyngeal and oropharyngeal swabs of COVID-19 patients. <i>Heliyon</i> , 2020, 6, e05143.	1.4	23
27	Evaluation of virological response and resistance profile in HIV-1 infected patients starting a first-line integrase inhibitor-based regimen in clinical settings. <i>Journal of Clinical Virology</i> , 2020, 130, 104534.	1.6	11
28	Missed Opportunities of Flu Vaccination in Italian Target Categories: Insights from the Online EPICOVID 19 Survey. <i>Vaccines</i> , 2020, 8, 669.	2.1	8
29	Long-Term SARS-CoV-2 Infection Associated with Viral Dissemination in Different Body Fluids Including Bile in Two Patients with Acute Cholecystitis. <i>Life</i> , 2020, 10, 302.	1.1	15
30	Mild clinical manifestations of SARS-CoV-2 related pneumonia in two patients with multiple sclerosis under treatment with ocrelizumab. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 45, 102442.	0.9	18
31	Analysis of ACE2 genetic variants in 131 Italian SARS-CoV-2-positive patients. <i>Human Genomics</i> , 2020, 14, 29.	1.4	60
32	HLA allele frequencies and susceptibility to COVID-19 in a group of 99 Italian patients. <i>Hla</i> , 2020, 96, 610-614.	0.4	130
33	Appraisal of a Simple and Effective RT-qPCR Assay for Evaluating the Reverse Transcriptase Activity in Blood Samples from HIV-1 Patients. <i>Pathogens</i> , 2020, 9, 1047.	1.2	3
34	A Hyper-Glycosylation of HBV Surface Antigen Correlates with HBsAg-Negativity at Immunosuppression-Driven HBV Reactivation in Vivo and Hinders HBsAg Recognition In Vitro. <i>Viruses</i> , 2020, 12, 251.	1.5	8
35	Whole genome sequencing of carbapenem-resistant Klebsiella pneumoniae: evolutionary analysis for outbreak investigation. <i>Future Microbiology</i> , 2020, 15, 203-212.	1.0	7
36	Budget Impact Analysis of Dalbavancin in the Treatment of Acute Bacterial Skin and Skin Structure Infections in Three European Countries. <i>Clinical Drug Investigation</i> , 2020, 40, 305-318.	1.1	15

#	ARTICLE	IF	CITATIONS
37	Tuberculosis-Related Hospitalizations in a Low-Incidence Country: A Retrospective Analysis in Two Italian Infectious Diseases Wards. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 124.	1.2	3
38	Key mutations in the C-terminus of the HBV surface glycoprotein correlate with lower HBsAg levels <i>in vivo</i> , hinder HBsAg secretion <i>in vitro</i> and reduce HBsAg structural stability in the setting of HBeAg-negative chronic HBV genotype-D infection. <i>Emerging Microbes and Infections</i> , 2020, 9, 928-939.	3.0	5
39	Plant microRNAs from <i>Moringa oleifera</i> Regulate Immune Response and HIV Infection. <i>Frontiers in Pharmacology</i> , 2020, 11, 620038.	1.6	14
40	Subjective neurological symptoms frequently occur in patients with SARS-CoV2 infection. <i>Brain, Behavior, and Immunity</i> , 2020, 88, 11-16.	2.0	159
41	Self-Reported Symptoms of SARS-CoV-2 Infection in a Nonhospitalized Population in Italy: Cross-Sectional Study of the EPICoVID19 Web-Based Survey. <i>JMIR Public Health and Surveillance</i> , 2020, 6, e21866.	1.2	63
42	Bacteriophage therapy: an overview and the position of Italian Society of Infectious and Tropical Diseases. <i>Infezioni in Medicina</i> , 2020, 28, 322-331.	0.7	3
43	Beyond Italian guidelines in the management of HIV-positive patient. <i>Infezioni in Medicina</i> , 2020, 28, 587-596.	0.7	0
44	Impact of Initial Antifungal Therapy on the Outcome of Patients With Candidemia and Septic Shock Admitted to Medical Wards: A Propensity Score-Adjusted Analysis. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz251.	0.4	11
45	Remission of an HHV8-related extracavitary primary effusion lymphoma in an HIV-positive patient during antiretroviral treatment containing dolutegravir. <i>AIDS Research and Therapy</i> , 2019, 16, 15.	0.7	8
46	Hepatitis B virus reactivation sustained by a hepatitis B virus surface antigen immune-escape mutant isolate in a patient who was hepatitis B core antibody positive during treatment with sofosbuvir and velpatasvir for hepatitis C virus infection: a case report. <i>Journal of Medical Case Reports</i> , 2019, 13, 299.	0.4	2
47	Quantification of HIV-DNA and residual viremia in patients starting ART by droplet digital PCR: Their dynamic decay and correlations with immunological parameters and virological success. <i>Journal of Clinical Virology</i> , 2019, 117, 61-67.	1.6	24
48	Oral and anal high-risk human papilloma virus infection in HIV-positive men who have sex with men over a 24-month longitudinal study: complexity and vaccine implications. <i>BMC Public Health</i> , 2019, 19, 645.	1.2	10
49	Characterisation of HIV-1 molecular transmission clusters among newly diagnosed individuals infected with non-B subtypes in Italy. <i>Sexually Transmitted Infections</i> , 2019, 95, 619-625.	0.8	18
50	Very High Pre-Therapy Viral Load is a Predictor of Virological Rebound in HIV-1-Infected Patients Starting a Modern First-Line Regimen. <i>Antiviral Therapy</i> , 2019, 24, 321-331.	0.6	4
51	Role of pretreatment variables on plasma HIV RNA value at the sixth month of antiretroviral therapy including all first line drugs in HIV naïve patients: A path analysis approach. <i>PLoS ONE</i> , 2019, 14, e0213160.	1.1	1
52	A snapshot of virological presentation and outcome of immunosuppression-driven HBV reactivation from real clinical practice: Evidence of a relevant risk of death and evolution from silent to chronic infection. <i>Journal of Viral Hepatitis</i> , 2019, 26, 846-855.	1.0	9
53	Integrase strand transfer inhibitor-based regimen is related with a limited HIV-1 V3 loop evolution in clinical practice. <i>Virus Genes</i> , 2019, 55, 290-297.	0.7	0
54	Cerebrospinal fluid HIV-1 escape according to different thresholds and underlying comorbidities. <i>Aids</i> , 2019, 33, 759-762.	1.0	19

#	ARTICLE	IF	CITATIONS
55	Na ⁺ ve/Effector CD4 T cell ratio as a useful predictive marker of immune reconstitution in late presenter HIV patients: A multicenter study. <i>PLoS ONE</i> , 2019, 14, e0225415.	1.1	15
56	An in-depth analysis of nosocomial bloodstream infections due to Gram-negative bacilli: clinical features, microbiological characteristics and predictors of mortality in a 1 year, prospective study in a large tertiary care Italian hospital. <i>Infectious Diseases</i> , 2019, 51, 12-22.	1.4	8
57	Viro-Immunological Response of Drug-Naive HIV-1-Infected Patients Starting a First-Line Regimen with Viraemia >500,000 Copies/ml in Clinical Practice. <i>Antiviral Therapy</i> , 2018, 23, 249-257.	0.6	10
58	Cortical sources of resting state electroencephalographic rhythms probe brain function in na ⁺ ve HIV individuals. <i>Clinical Neurophysiology</i> , 2018, 129, 431-441.	0.7	5
59	Soluble CD163 and soluble CD14 plasma levels but not cellular HIV-DNA decrease during successful interferon-free anti-HCV therapy in HIV-1+HCV co-infected patients on effective combined anti-HIV treatment. <i>Medical Microbiology and Immunology</i> , 2018, 207, 183-194.	2.6	20
60	766. Migration Flows and Increase of Extrapulmonary Tuberculosis in a Low Prevalence Setting: A Retrospective Analysis in Two Italian Centers. <i>Open Forum Infectious Diseases</i> , 2018, 5, S275-S275.	0.4	0
61	Genetic divergence of HIV-1 B subtype in Italy over the years 2003-2016 and impact on CTL escape prevalence. <i>Scientific Reports</i> , 2018, 8, 15739.	1.6	2
62	Cytomegalovirus, Epstein-Barr virus and human herpesvirus 8 salivary shedding in HIV positive men who have sex with men with controlled and uncontrolled plasma HIV viremia: a 24-month longitudinal study. <i>BMC Infectious Diseases</i> , 2018, 18, 683.	1.3	11
63	Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline viro-immunological status and outcome in patients under first-line ART. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 3460-3470.	1.3	8
64	HDV Can Constrain HBV Genetic Evolution in HBsAg: Implications for the Identification of Innovative Pharmacological Targets. <i>Viruses</i> , 2018, 10, 363.	1.5	4
65	Trend of estimated glomerular filtration rate during ombistasvir/paritaprevir/ritonavir plus dasabuvir ± ribavirin in HIV/HCV co-infected patients. <i>PLoS ONE</i> , 2018, 13, e0192627.	1.1	6
66	High rates of chronic HBV genotype E infection in a group of migrants in Italy from West Africa: Virological characteristics associated with poor immune clearance. <i>PLoS ONE</i> , 2018, 13, e0195045.	1.1	15
67	Biomarkers of monitoring and functional reserve of physiological systems over time in HIV: expert opinions for effective secondary prevention. <i>New Microbiologica</i> , 2018, 41, 1-25.	0.1	21
68	NK cells of HIV-1-infected patients with poor CD4+ T-cell reconstitution despite suppressive HAART show reduced IFN- γ production and high frequency of autoreactive CD56bright cells. <i>Immunology Letters</i> , 2017, 190, 185-193.	1.1	16
69	Time course of cellular HIV-DNA and low-level HIV viremia in HIV+HCV co-infected patients whose HCV infection had been successfully treated with directly acting antivirals. <i>Medical Microbiology and Immunology</i> , 2017, 206, 419-428.	2.6	11
70	Comparative Evaluation of Subtyping Tools for Surveillance of Newly Emerging HIV-1 Strains. <i>Journal of Clinical Microbiology</i> , 2017, 55, 2827-2837.	1.8	18
71	Drug resistance in B and non-B subtypes amongst subjects recently diagnosed as primary/recent or chronic HIV-infected over the period 2013-2016: Impact on susceptibility to first-line strategies including integrase strand-transfer inhibitors. <i>Journal of Global Antimicrobial Resistance</i> , 2017, 10, 106-112.	0.9	17
72	Structural equation modelling of viral tropism reveals its impact on achieving viral suppression within 6 months in treatment-naive HIV-1-infected patients after combination antiretroviral therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 220-226.	1.3	2

#	ARTICLE	IF	CITATIONS
73	Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: Data from the Icona cohort. PLoS ONE, 2017, 12, e0177402.	1.1	15
74	Paravalvular leak of a mechanical mitral valve prosthesis associated with Burkholderia cepacia subacute endocarditis: a rare case successfully treated by multidisciplinary approach. Kardiochirurgia I Torakochirurgia Polska, 2017, 3, 200-202.	0.1	2
75	Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients. PLoS ONE, 2017, 12, e0171611.	1.1	10
76	Novel HBsAg mutations correlate with hepatocellular carcinoma, hamper HBsAg secretion and promote cell proliferation <i>in vitro</i> . Oncotarget, 2017, 8, 15704-15715.	0.8	9
77	Liver stiffness is not associated with short- and long-term plasma HIV RNA replication in immunocompetent patients with HIV infection and with HIV/HCV coinfection. Annals of Gastroenterology, 2017, 30, 534-541.	0.4	1
78	Antiretroviral therapy affects the z-score index of deviant cortical EEG rhythms in naïve HIV individuals. NeuroImage: Clinical, 2016, 12, 144-156.	1.4	8
79	Brain and cognitive functions in two groups of naïve HIV patients selected for a different plan of antiretroviral therapy: A qEEG study. Clinical Neurophysiology, 2016, 127, 3455-3469.	0.7	4
80	The HIV-1 reverse transcriptase polymorphism A98S improves the response to tenofovir disoproxil fumarate+emtricitabine-containing HAART both in vivo and in vitro. Journal of Global Antimicrobial Resistance, 2016, 7, 1-7.	0.9	3
81	Genotypic resistance test in proviral DNA can identify resistance mutations never detected in historical genotypic test in patients with low level or undetectable HIV-RNA. Journal of Clinical Virology, 2016, 82, 94-100.	1.6	35
82	Impact of HIV-1 tropism on the emergence of non-AIDS events in HIV-infected patients receiving fully suppressive antiretroviral therapy. Aids, 2016, 30, 731-741.	1.0	12
83	Abnormal cortical sources of resting state electroencephalographic rhythms in single treatment-naïve HIV individuals: A statistical z-score index. Clinical Neurophysiology, 2016, 127, 1803-1812.	0.7	16
84	Total HIV-1 DNA detection and quantification in peripheral blood by COBAS®AmpliPrep/COBAS®TaqMan® HIV-1 Test, v2.0. Clinical Chemistry and Laboratory Medicine, 2016, 54, e57-9.	1.4	4
85	Impact of Previous Invasive Fungal Infections on the Outcome of Patients Undergoing Allogeneic Hematopoietic Stem Cells. Blood, 2016, 128, 5748-5748.	0.6	0
86	Expression and Function of NKG2D Is Impaired in CD8+ T Cells of Chronically HIV-1-Infected Patients Without ART. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 70, 347-356.	0.9	4
87	Willingness to pay for innovation: the case of the anti-HCV drugs from the Italian National Health Service perspective. Global & Regional Health Technology Assessment, 2015, 2, GRHTA.5000201.	0.2	3
88	Recent Transmission Clustering of HIV-1 C and CRF17_BF Strains Characterized by NNRTI-Related Mutations among Newly Diagnosed Men in Central Italy. PLoS ONE, 2015, 10, e0135325.	1.1	21
89	HIV Replication at Low Copy Number and its Correlation with the HIV Reservoir: A Clinical Perspective. Current HIV Research, 2015, 13, 250-257.	0.2	37
90	Hepatitis C virus RNA levels at week-2 of telaprevir/boceprevir administration are predictive of virological outcome. Digestive and Liver Disease, 2015, 47, 157-163.	0.4	5

#	ARTICLE	IF	CITATIONS
91	Microbiologic characteristics and predictors of mortality in bloodstream infections in intensive care unit patients: A 1-year, large, prospective surveillance study in 5 Italian hospitals. <i>American Journal of Infection Control</i> , 2015, 43, 1178-1183.	1.1	22
92	Detection and correlates of <i>Chlamydomphila pneumoniae</i> among children with acute respiratory infections. <i>Journal of Pediatric Infectious Diseases</i> , 2015, 05, 249-254.	0.1	1
93	Genotypic Tropism Testing in HIV-1 Proviral DNA Can Provide Useful Information at Low-Level Viremia. <i>Journal of Clinical Microbiology</i> , 2015, 53, 2935-2941.	1.8	6
94	Specific mutations in the C-terminus domain of HBV surface antigen significantly correlate with low level of serum HBV-DNA in patients with chronic HBV infection. <i>Journal of Infection</i> , 2015, 70, 288-298.	1.7	11
95	Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression. <i>Hepatology</i> , 2015, 61, 823-833.	3.6	109
96	Antiretroviral therapy effects on sources of cortical rhythms in HIV subjects: Responders vs. Mild Responders. <i>Clinical Neurophysiology</i> , 2015, 126, 68-81.	0.7	7
97	Health policy model: long-term predictive results associated with the management of hepatitis C virus-induced diseases in Italy. <i>ClinicoEconomics and Outcomes Research</i> , 2014, 6, 303.	0.7	19
98	Budget impact analysis of antiretroviral less drug regimen simplification in HIV-positive patients on the Italian National Health Service. <i>ClinicoEconomics and Outcomes Research</i> , 2014, 6, 409.	0.7	7
99	18-Fluoro-2-deoxyglucose positron emission tomographyâ€“computed tomography: an additional tool in the diagnosis of prosthetic valve endocarditis. <i>International Journal of Infectious Diseases</i> , 2014, 28, 219-224.	1.5	75
100	Reliability and Clinical Relevance of the HIV-1 Drug Resistance Test in Patients With Low Viremia Levels. <i>Clinical Infectious Diseases</i> , 2014, 58, 1156-1164.	2.9	67
101	Liver Enzyme Elevation During Darunavir-Based Antiretroviral Treatment in HIV-1â€“infected Patients With or Without Hepatitis C Coinfection: Data from the ICONA Foundation Cohort. <i>HIV Clinical Trials</i> , 2014, 15, 151-160.	2.0	10
102	Cortical sources of resting-state EEG rhythms in â€œexperiencedâ€•HIV subjects under antiretroviral therapy. <i>Clinical Neurophysiology</i> , 2014, 125, 1792-1802.	0.7	19
103	A Very Low Geno2pheno False Positive Rate Is Associated with Poor Viro-Immunological Response in Drug-Naïve Patients Starting a First-Line HAART. <i>PLoS ONE</i> , 2014, 9, e105853.	1.1	9
104	A stable CC-chemokine receptor (CCR)-5 tropic virus is correlated with the persistence of HIV RNA at less than 2.5 copies in successfully treated naïve subjects. <i>BMC Infectious Diseases</i> , 2013, 13, 314.	1.3	7
105	Anti-HBV treatment induces novel reverse transcriptase mutations with reflective effect on HBV S antigen. <i>Journal of Infection</i> , 2013, 67, 303-312.	1.7	23
106	Decreasing trends of drug resistance and increase of non-B subtypes amongst subjects recently diagnosed as HIV-infected over the period 2004â€“2012 in the Veneto Region, Italy. <i>Journal of Global Antimicrobial Resistance</i> , 2013, 1, 201-206.	0.9	6
107	Soluble ligands for the NKG2D receptor are released during HIVâ€“1 infection and impair NKG2D expression and cytotoxicity of NK cells. <i>FASEB Journal</i> , 2013, 27, 2440-2450.	0.2	75
108	Impact of Pre-Therapy Viral Load on Virological Response to Modern First-Line Haart. <i>Antiviral Therapy</i> , 2013, 18, 867-876.	0.6	34

#	ARTICLE	IF	CITATIONS
109	Durability of Lopinavir/ritonavir mono-therapy in individuals with viral load ≥ 50 copies/mL in the observational setting. <i>Antiviral Therapy</i> , 2013, 19, 319-324.	0.6	5
110	The Genotypic False Positive Rate Determined by V3 Population Sequencing Can Predict the Burden of HIV-1 CXCR4-using Species Detected by Pyrosequencing. <i>PLoS ONE</i> , 2013, 8, e53603.	1.1	14
111	Inhibition of Dual/Mixed Tropic HIV-1 Isolates by CCR5-Inhibitors in Primary Lymphocytes and Macrophages. <i>PLoS ONE</i> , 2013, 8, e68076.	1.1	14
112	Nevirapine use, prolonged antiretroviral therapy and high CD4 nadir values are strongly correlated with undetectable HIV-DNA and -RNA levels and CD4 cell gain. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 2932-2938.	1.3	17
113	Baseline Cellular HIV DNA Load Predicts HIV DNA Decline and Residual HIV Plasma Levels during Effective Antiretroviral Therapy. <i>Journal of Clinical Microbiology</i> , 2012, 50, 258-263.	1.8	48
114	HIV neutralizing antibody titer during structured treatment interruption of highly active antiretroviral therapy. <i>Aids</i> , 2012, 26, 1451-1452.	1.0	2
115	Late hepatitis B virus reactivation after lamivudine prophylaxis interruption in an anti-HBs-positive and anti-HBc-negative patient treated with rituximab-containing therapy. <i>Journal of Infection</i> , 2012, 65, 180-183.	1.7	38
116	Characterization of drug resistance mutations in naïve and ART-treated patients infected with HIV-1 in Yaounde, Cameroon. <i>Journal of Medical Virology</i> , 2012, 84, 721-727.	2.5	31
117	Janus-faced liposomes enhance antimicrobial innate immune response in <i>Mycobacterium tuberculosis</i> infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, E1360-8.	3.3	60
118	Novel HBsAg markers tightly correlate with occult HBV infection and strongly affect HBsAg detection. <i>Antiviral Research</i> , 2012, 93, 86-93.	1.9	71
119	Determinants of access to experimental antiretroviral drugs in an Italian cohort of patients with HIV: a multilevel analysis. <i>BMC Health Services Research</i> , 2012, 12, 38.	0.9	0
120	HCV Genotypes Are Differently Prone to the Development of Resistance to Linear and Macrocyclic Protease Inhibitors. <i>PLoS ONE</i> , 2012, 7, e39652.	1.1	78
121	Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA study group. <i>New Microbiologica</i> , 2012, 35, 17-25.	0.1	19
122	Identification and Structural Characterization of Novel Genetic Elements in the HIV-1 V3 Loop Regulating Coreceptor Usage. <i>Antiviral Therapy</i> , 2011, 16, 1035-1045.	0.6	23
123	HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro. <i>Antiviral Research</i> , 2011, 90, 42-53.	1.9	27
124	KSHV DNA viremia correlates with low CD4+ cell count in Italian Males at the time of diagnosis of HIV infection. <i>Journal of Medical Virology</i> , 2011, 83, 384-390.	2.5	6
125	Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 1886-1896.	1.3	56
126	Once-a-Day (QD) vs Twice-Daily (BID) Nevirapine as Simplification in PITreated Patients After 2 mos. of BID Induction. <i>Current HIV Research</i> , 2011, 9, 166-173.	0.2	1

#	ARTICLE	IF	CITATIONS
127	A case of rhabdomyolysis associated with raltegravir use. <i>Aids</i> , 2010, 24, 473-475.	1.0	26
128	Procalcitonin is a reliable marker of severe systemic infection in neutropenic haematological patients with mucositis. <i>American Journal of Hematology</i> , 2010, 85, 380-383.	2.0	12
129	Secondary Integrase Resistance Mutations Found in HIV-1 Minority Quasispecies in Integrase Therapy-Naive Patients Have Little or No Effect on Susceptibility to Integrase Inhibitors. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 3938-3948.	1.4	36
130	Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study Group. <i>New Microbiologica</i> , 2010, 33, 195-206.	0.1	35
131	Ultrasensitive assessment of residual HIV viraemia in HAART-treated patients with persistently undetectable plasma HIV RNA: A cross-sectional evaluation. <i>Journal of Medical Virology</i> , 2009, 81, 400-405.	2.5	49
132	Prognostic factors of long-term CD4+count-guided interruption of antiretroviral treatment. <i>Journal of Medical Virology</i> , 2009, 81, 481-487.	2.5	10
133	Multidrug resistance after lamivudine therapy for chronic hepatitis B. <i>International Journal of Infectious Diseases</i> , 2009, 13, e133-e134.	1.5	1
134	HIV-1 Residual Viremia and Proviral DNA in Patients with Suppressed Plasma Viral Load (< 400) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 4	0.2	31
135	Stopping antiretroviral therapy: role for therapeutic drug monitoring. <i>Aids</i> , 2008, 22, 315-316.	1.0	2
136	Both Human Immunodeficiency Virus Cellular DNA Sequencing and Plasma RNA Sequencing Are Useful for Detection of Drug Resistance Mutations in Blood Samples from Antiretroviral-Drug-Naive Patients. <i>Journal of Clinical Microbiology</i> , 2007, 45, 3484-3484.	1.8	1
137	Both Human Immunodeficiency Virus Cellular DNA Sequencing and Plasma RNA Sequencing Are Useful for Detection of Drug Resistance Mutations in Blood Samples from Antiretroviral-Drug-Naive Patients. <i>Journal of Clinical Microbiology</i> , 2007, 45, 1783-1788.	1.8	33
138	Sex issues in HIV-1-infected persons during highly active antiretroviral therapy: a systematic review. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 60, 724-732.	1.3	124
139	Human herpesvirus 8 and human herpesvirus 2 infections in prison population. <i>Journal of Medical Virology</i> , 2007, 79, 167-173.	2.5	5
140	Cellular HIV-1 DNA quantitation in patients during simplification therapy with protease inhibitor-sparing regimens. <i>Journal of Medical Virology</i> , 2007, 79, 880-886.	2.5	22
141	Virological response to Salvage Therapy in HIV-Infected Persons Carrying the Reverse Transcriptase K65R Mutation. <i>Antiviral Therapy</i> , 2007, 12, 1175-1184.	0.6	22
142	Long-Term Follow-Up of Previous Hepatitis C Virus Positive Nonresponders to Interferon Monotherapy Successfully Retreated with Combination Therapy: Are They Really Cured?. <i>American Journal of Gastroenterology</i> , 2006, 101, 1811-1816.	0.2	25
143	Drug-resistance mutations can be archived very early in HIV primary infection. <i>Aids</i> , 2006, 20, 1337-1338.	1.0	7
144	Residual viraemia in subjects with chronic HIV infection and viral load < 50 copies/ml: the impact of highly active antiretroviral therapy. <i>Aids</i> , 2005, 19, 1843-1847.	1.0	47

#	ARTICLE	IF	CITATIONS
145	Clinical outcome after 4 years follow-up of HIV-seropositive subjects with incomplete virologic or immunologic response to HAART. <i>Journal of Medical Virology</i> , 2005, 76, 153-160.	2.5	66
146	Association between Cellular Human Immunodeficiency Virus DNA Level and Immunological Parameters in Patients with Undetectable Plasma Viremia Level during Highly Active Antiretroviral Therapy. <i>Journal of Clinical Microbiology</i> , 2005, 43, 6183-6185.	1.8	21
147	Short Communication: Non-B HIV Type 1 Subtypes: Replicative Capacity and Response to Antiretroviral Therapy. <i>AIDS Research and Human Retroviruses</i> , 2004, 20, 816-818.	0.5	13
148	Viral growth assay to evaluate the replicative capacity of HIV-1 isolates. <i>Journal of Virological Methods</i> , 2004, 115, 199-205.	1.0	2
149	Human herpesvirus-8 infection in pregnancy and labor: Lack of evidence of vertical transmission. <i>Journal of Medical Virology</i> , 2004, 72, 462-466.	2.5	15
150	In vitro fluconazole susceptibility of 1565 clinical isolates of candida species evaluated by the disk diffusion method performed using NCCLS M44-A guidelines. <i>Diagnostic Microbiology and Infectious Disease</i> , 2004, 50, 187-192.	0.8	12
151	Prevalence of HHV-8 Infection in Albanian Adults and Association with HBV and HCV. <i>European Journal of Epidemiology</i> , 2003, 19, 467-469.	2.5	5
152	Replication capacity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapy. <i>Journal of Medical Virology</i> , 2003, 69, 1-6.	2.5	59
153	Effect of multiple herpesvirus infections on the progression of HIV disease in a cohort of HIV seroconverters. <i>Journal of Medical Virology</i> , 2003, 69, 182-187.	2.5	9
154	Drug-Associated Resistance Mutations in Plasma and Peripheral Blood Mononuclear Cells of Human Immunodeficiency Virus Type 1-Infected Patients for Whom Highly Active Antiretroviral Therapy Is Failing. <i>Journal of Clinical Microbiology</i> , 2003, 41, 1760-1762.	1.8	28
155	Does the Risk of Abortion Increase in Women with High Human Herpesvirus-8 Antibody Titers?. <i>Journal of Infectious Diseases</i> , 2003, 188, 173-174.	1.9	9
156	Human Immunodeficiency Virus Polymorphisms and Zidovudine Resistance. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 2714-2715.	1.4	0
157	High Prevalence of M184 Mutation among Patients with Viroimmunologic Discordant Responses to Highly Active Antiretroviral Therapy and Outcomes after Change of Therapy Guided by Genotypic Analysis. <i>Journal of Clinical Microbiology</i> , 2003, 41, 3007-3012.	1.8	14
158	Stavudine Protective Function and Emergence of Lamivudine Resistance. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 1176-1176.	1.4	0
159	Reply to 'Different degree of immune recovery using antiretroviral regimens with protease inhibitors or non-nucleosides', by Barreiro et al.. <i>Aids</i> , 2003, 17, 447-448.	1.0	0
160	Calibrated Real-Time PCR Assay for Quantitation of Human Herpesvirus 8 DNA in Biological Fluids. <i>Journal of Clinical Microbiology</i> , 2002, 40, 4652-4658.	1.8	45
161	Primary Human Herpesvirus 8 Infection in Immunocompetent Children. <i>JAMA - Journal of the American Medical Association</i> , 2002, 287, 1295.	3.8	130
162	Discordance between Genotypic and Phenotypic Drug Resistance Profiles in Human Immunodeficiency Virus Type 1 Strains Isolated from Peripheral Blood Mononuclear Cells. <i>Journal of Clinical Microbiology</i> , 2002, 40, 335-340.	1.8	14

#	ARTICLE	IF	CITATIONS
163	Prevalence Trend and Correlates of HHV-8 Infection in HIV-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2002, 29, 295-299.	0.9	13
164	Discordant response to antiretroviral therapy. <i>Aids</i> , 2002, 16, 1877-1885.	1.0	18
165	A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C relapsing after interferon monotherapy. <i>Hepatology</i> , 2002, 36, 959-966.	3.6	0
166	Retrospective analysis of HHV-8 viremia and cellular viral load in HIV-seropositive patients receiving interleukin 2 in combination with antiretroviral therapy. <i>Blood</i> , 2002, 100, 1575-1578.	0.6	11
167	NK cell activity controls human herpesvirus 8 latent infection and is restored upon highly active antiretroviral therapy in AIDS patients with regressing Kaposi's sarcoma. <i>European Journal of Immunology</i> , 2002, 32, 2711-2720.	1.6	84
168	Identification of cytotoxic T lymphocyte epitopes of human herpesvirus 8. <i>Immunology</i> , 2002, 106, 395-403.	2.0	45
169	Human herpesvirus 8 cytoviraemia rebound in a patient with Kaposi's sarcoma after a short interruption of efficient antiretroviral therapy. <i>Aids</i> , 2002, 16, 1089-1091.	1.0	4
170	Retrospective analysis of HHV-8 viremia and cellular viral load in HIV-seropositive patients receiving interleukin 2 in combination with antiretroviral therapy. <i>Blood</i> , 2002, 100, 1575-8.	0.6	3
171	No Protective Effect of Acyclovir on HIV Disease Progression in a Cohort of Hsv-2 HIV-Infected Individuals. <i>Antiviral Therapy</i> , 2002, 7, 289-291.	0.6	7
172	Interferon and amantadine in combination as initial treatment for chronic hepatitis C patients. <i>Journal of Hepatology</i> , 2001, 35, 517-521.	1.8	31
173	Two-year surveillance on fluconazole susceptibility of <i>Candida</i> spp isolates in a general and university hospital in Rome. <i>Diagnostic Microbiology and Infectious Disease</i> , 2001, 41, 23-27.	0.8	9
174	Treatment with interferon- α 2b of naive non-cirrhotic patients with chronic hepatitis C according to viraemia and genotype. Results of a randomized multicentre study. <i>European Journal of Gastroenterology and Hepatology</i> , 2001, 13, 149-155.	0.8	6
175	Human immunodeficiency virus-1 specific and natural cellular immunity in HIV seronegative subjects with multiple sexual exposures to virus. <i>Journal of Medical Virology</i> , 2001, 64, 232-237.	2.5	11
176	Kaposi's sarcoma-associated herpesvirus serology in Europe and Uganda: Multicentre study with multiple and novel assays. <i>Journal of Medical Virology</i> , 2001, 65, 123-132.	2.5	56
177	Failure of stavudine-lamivudine combination therapy in antiretroviral-naive patients with AZT-Like HIV-1 resistance mutations. <i>Journal of Medical Virology</i> , 2001, 65, 631-636.	2.5	12
178	Human herpes virus-8 infection among pregnant women and their children: Results from the sardinia-IDDM study 2. <i>International Journal of Cancer</i> , 2001, 91, 740-741.	2.3	19
179	A seroprevalence study of human herpesvirus type 8 (HHV8) in eastern and Central Africa and in the Mediterranean area. <i>European Journal of Epidemiology</i> , 2001, 17, 871-876.	2.5	47
180	A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C not responding to interferon alone. <i>Hepatology</i> , 2001, 34, 133-138.	3.6	48

#	ARTICLE	IF	CITATIONS
181	Correlation between Enzyme-Linked Immunosorbent Assay and Immunofluorescence Assay with Lytic Antigens for Detection of Antibodies to Human Herpesvirus 8. <i>Vaccine Journal</i> , 2001, 8, 203-205.	2.6	5
182	Neutralizing Antibodies against Autologous Human Immunodeficiency Virus Type 1 Isolates in Patients with Increasing CD4 Cell Counts despite Incomplete Virus Suppression during Antiretroviral Treatment. <i>Vaccine Journal</i> , 2001, 8, 822-824.	2.6	6
183	Clearance of Human Herpesvirus 8 from Blood and Regression of Leukopenia Associated Aggressive Classic Kaposi's Sarcoma during Interferon Therapy: A Case Report. <i>Clinical Infectious Diseases</i> , 2001, 33, 1782-1785.	2.9	7
184	Human herpes virus-8 infection among pregnant women and their children: Results from the sardinia-IDDM study 2. , 2001, 91, 740.		1
185	Absence of an effect of herpes simplex virus type 2 infection on HIV disease progression: data from a cohort of HIV-positive individuals with known date of seroconversion. <i>Aids</i> , 2001, 15, 133-135.	1.0	11
186	Efficacy of cidofovir on human herpesvirus 8 viraemia and Kaposi's sarcoma progression in two patients with AIDS. <i>Aids</i> , 2001, 15, 2061-2062.	1.0	50
187	Cellular proviral HIV-DNA decline and viral isolation in naïve subjects with <5000 copies/ml of HIV-RNA and >500 Å– 106/l CD4 cells treated with highly active antiretroviral therapy. <i>Aids</i> , 2000, 14, 23-29.	1.0	33
188	Incidence of Kaposi's sarcoma and HHV-8 seroprevalence among homosexual men with known dates of HIV seroconversion. <i>Aids</i> , 2000, 14, 1647-1653.	1.0	28
189	Prevalence and Risk Factors for Human Herpesvirus 8 Infection in Northern Cameroon. <i>Sexually Transmitted Diseases</i> , 2000, 27, 159-164.	0.8	51
190	Distribution of the CCR5 Delta32 Allele in Italian HIV Type 1-Infected and Normal Individuals. <i>AIDS Research and Human Retroviruses</i> , 2000, 16, 181-182.	0.5	17
191	Reduction of IFN-g and IL-2 production by peripheral lymphocytes of HIV-exposed seronegative subjects. <i>Aids</i> , 1999, 13, 1333-1336.	1.0	13
192	Alpha Interferon Inhibits Human Herpesvirus 8 (HHV-8) Reactivation in Primary Effusion Lymphoma Cells and Reduces HHV-8 Load in Cultured Peripheral Blood Mononuclear Cells. <i>Journal of Virology</i> , 1999, 73, 4029-4041.	1.5	70
193	Saquinavir delays the emergence of zidovudine resistance in HIV-1 seropositive patients treated with combination therapy. , 1998, 56, 332-336.		1
194	HIV phenotype switching during antiretroviral therapy. <i>Aids</i> , 1997, 11, 1211-1217.	1.0	19
195	Human Immunodeficiency Virus Infection of Human Bone Marrow Stromal Myoid Cells. <i>Scandinavian Journal of Infectious Diseases</i> , 1996, 28, 335-340.	1.5	7
196	Saquinavir/zidovudine combination in patients with advanced HIV infection and no prior antiretroviral therapy: CD4 + lymphocyte/plasma RNA changes, and emergence of HIV strains with reduced phenotypic sensitivity. <i>Antiviral Research</i> , 1996, 29, 91-93.	1.9	28
197	In vitro Activity of a New Antibacterial Drug, Trospsectomycin Sulphate (U-63,366F), against <i>Bacteroides; Strains Isolated from the Vagina. <i>Chemotherapy</i> , 1993, 39, 124-127.	0.8	0
198	A rapid microneutralization assay for the measurement of neutralizing antibody reactive with human cytomegalovirus. <i>Journal of Virological Methods</i> , 1989, 23, 157-167.	1.0	181

#	ARTICLE	IF	CITATIONS
199	Cost-utility analysis of ceftolozane/tazobactam vs meropenem in patients with hospital-acquired pneumonia (HABP) or ventilator-associated pneumonia (VABP). <i>Global & Regional Health Technology Assessment</i> , 0, 9, 45-57.	0.2	2